Research and development on depression, dementia and other conditions using violet light
First written in FY2022. 8 of 12 entries say "Advanced", first in FY2024-Q1. Latest entry: 2026-06-24.
No other company in this theme has enough history to compare yet.
- 2026-06-24AdvancedOther Disclosures
「Research on elucidating the function of the non-visual receptor OPN5 in the central nervous system and the molecular characteristics and physiological functions of human OPN5.」
The company established a joint research center with teams from Keio University and the RIKEN Center for Brain Science, giving concrete form to research to elucidate and deepen understanding of OPN5 in violet-light-related research targeting central nervous system diseases and other conditions. - FY2026AdvancedAnnual report
「The safety of the device has been confirmed in all studies. In depression, the results showed efficacy, while in Parkinson’s disease, the results suggested that violet-light irradiation may improve some symptoms. Based on the data obtained to date, the company is conducting partnership negotiations for commercialization.」
For TLG-005, the company obtained results showing efficacy in depression and results suggesting an improvement effect in Parkinson’s disease, and continues partnership negotiations for commercialization. - FY2026-H1AdvancedAnnual report
「In business development activities based on these R&D activities, the company is advancing negotiations with multiple companies in Japan and overseas for out-licensing the medical device TLG-005, which applies violet-light technology in the field of brain diseases.」
It states that negotiations with multiple companies in Japan and overseas are under way for the out-licensing of TLG-005. - FY2025-H1AdvancedAnnual report
「速報 results from the specified clinical research on TLG-005 for depression and Parkinson’s disease showed efficacy.」
It states that速報 results from the specified clinical research on TLG-005 for depression and Parkinson’s disease showed efficacy. - FY2024DroppedAnnual report
「In fiscal 2023, we completed the studies of depression and Parkinson's disease, and subject enrollment for mild cognitive impairment was also completed.」
While each study under TLG-005 reached the completion stage, a note stated that the project termination with Sumitomo Pharma Co., Ltd. was resolved on 22 May 2024, and the previous joint research project ended. - FY2024-Q3AdvancedAnnual report
「Subject enrollment in the specified clinical research studies for depression and Parkinson's disease under TLG-005 has also been completed. Following subject observation, we conducted statistical analysis and continued promoting subject enrollment for MCI (mild cognitive impairment).」
For TLG-005, following completion of subject enrollment for depression and Parkinson's disease, the studies progressed to observation and statistical analysis, while subject enrollment for MCI continued. - FY2024-Q2AdvancedAnnual report
「In business development, while advancing subject enrollment in the confirmatory clinical trial of TLG₋001, we completed subject enrollment in the specified clinical research studies for depression and Parkinson's disease under TLG₋005.」
For TLG-005, the company states that subject enrollment has been completed in the specified clinical research studies for depression and Parkinson's disease. - FY2024-Q1AdvancedAnnual report
「For the neurological disease pipeline TLG-005, subject enrollment in the specified clinical research study for Parkinson's disease has been completed, while enrollment for other diseases is continuing.」
For the neurological disease pipeline TLG-005, subject enrollment has been completed in the specified clinical research study for Parkinson's disease, demonstrating concrete progress in the research stage. - FY2023RestatedAnnual report
「We are conducting multiple specified clinical research studies for conditions including depression and mild cognitive impairment (MCI).」
We are continuing research into applying violet light to neurological diseases other than myopia, including depression and dementia. - FY2022First statedAnnual report
「We are conducting multiple specified clinical research studies for conditions including depression and mild cognitive impairment (MCI).」
Expanding the application of the technology to neurological and neuropsychiatric diseases beyond myopia as a research area.